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Abstract
Background: Fibrillins 1 (FBN1) and 2 (FBN2) are components of microfibrils, microfilaments that are present in many
connective tissues, either alone or in association with elastin. Marfan’s syndrome and congenital contractural
arachnodactyly (CCA) result from dominant mutations in the genes FBN1 and FBN2 respectively. Patients with both
conditions often present with specific muscle atrophy or weakness, yet this has not been reported in the mouse models. In
the case of Fbn1, this is due to perinatal lethality of the homozygous null mice making measurements of strength difficult. In
the case of Fbn2, four different mutant alleles have been described in the mouse and in all cases syndactyly was reported as
the defining phenotypic feature of homozygotes.
Methodology/Principal Findings: As part of a large-scale N-ethyl-N-nitrosourea (ENU) mutagenesis screen, we identified a
mouse mutant, Mariusz, which exhibited muscle weakness along with hindlimb syndactyly. We identified an amber
nonsense mutation in Fbn2 in this mouse mutant. Examination of a previously characterised Fbn2-null mutant, Fbn2fp,
identified a similar muscle weakness phenotype. The two Fbn2 mutant alleles complement each other confirming that the
weakness is the result of a lack of Fbn2 activity. Skeletal muscle from mutants proved to be abnormal with higher than
average numbers of fibres with centrally placed nuclei, an indicator that there are some regenerating muscle fibres.
Physiological tests indicated that the mutant muscle produces significantly less maximal force, possibly as a result of the
muscles being relatively smaller in Mariusz mice.
Conclusions: These findings indicate that Fbn2 is involved in integrity of structures required for strength in limb movement.
As human patients with mutations in the fibrillin genes FBN1 and FBN2 often present with muscle weakness and atrophy as
a symptom, Fbn2-null mice will be a useful model for examining this aspect of the disease process further.
Citation: Miller G, Neilan M, Chia R, Gheryani N, Holt N, et al. (2010) ENU Mutagenesis Reveals a Novel Phenotype of Reduced Limb Strength in Mice Lacking
Fibrillin 2. PLoS ONE 5(2): e9137. doi:10.1371/journal.pone.0009137
Editor: Ellen A. A. Nollen, University Medical Center Groningen, Netherlands
Received December 23, 2009; Accepted January 25, 2010; Published February 9, 2010
Copyright:  2010 Miller et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: t.n.dear@leeds.ac.uk
¤ Current address: Department of Neuroscience and Brain Technologies, Italian Institute of Technology, Genova, Italy
Introduction
Inherited neuromuscular disorders have a significant impact on
health and cause a wide variety of symptoms such as muscle
weakness, cardiomyopathy and/or mental retardation. Their
severity also varies significantly from being mild with little or no
symptoms (e.g. some cases of myotonic dystrophy) to severe where
life expectancy is shortened (e.g. Duchenne muscular dystrophy).
The primary tissue affected with each disorder ranges from the
nerves connecting the brain and spine to the muscles (e.g. spinal
muscular atrophy), the muscles themselves (e.g. Duchenne
muscular dystrophy) and the neuromuscular junctions (e.g.
myasthenia gravis).
In contrast to neuromuscular disorders connective tissue
disorders primarily affect the skin, cardiovascular system, skeleton
and eyes. Two such connective tissue disorders are Marfan’s
syndrome and Congenital Contractural Arachnodactyly (CCA),
which are caused by dominant mutations in the fibrillin-1 (FBN1)
and fibrillin-2 (FBN2) genes respectively [1,2]. Fibrillins are large
cysteine-rich glycoproteins found the extracellular matrix of
extensive tissues such as the lung, skin and blood vessels. Fibrillins
assemble into microfibrils that then become networks providing
structural support for the formation of elastic fibres. These
scaffolds of microfibrils also act as targets for growth factors
controlling differentiation and morphogenesis [3]. Not surprising-
ly, mutations in the fibrillin proteins can have serious consequenc-
es. For example patients with Marfan’s syndrome are usually very
tall, and can have one or more of the following symptoms: long
thin limbs, stretchy skin, hypermobile joints, arachnodactyly,
coloboma of the iris, scoliosis, learning disabilities, aneurysms and
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hypotonia, to name a few [4]. Patients with CCA, on the other
hand, whilst having some of the skeletal features in common with
Marfan’s syndrome, have a crumpled appearance of the ear helix
and congenital contractures, and do not typically have the ocular
and cardiovascular complications seen with Marfan’s syndrome
[5]. Of particular relevance to the study described here is that both
diseases affect the skeletal muscle seen as hypotonia in Marfan’s
syndrome and hypoplasia in CCA.
Mouse null mutants have been generated for both the Fbn1 and
Fbn2 genes and they prove to be imperfect models of the diseases.
Fbn1-null mutants do display the vascular abnormalities that have
been associated with Marfan’s syndrome but they do not appear to
manifest most other symptoms seen in humans with the condition
[6], while reported Fbn2-null mutants do not fully recapitulate the
CCA phenotype [7–9].
ENU mutagenesis is a valuable tool for uncovering mutations
that affect muscle development and function. Herein, we report
the identification of a mutant, Mariusz, in a recessive ENU
mutagenesis screen. Homozygous Mariusz mice suffer from a
profound muscle weakness and fusion of hind paw digits. We have
identified that Mariusz mice carry a nonsense mutation in the Fbn2
gene. This mutant is an important model for studying the
pathogenic mechanisms underlying muscle weakness and identifies
a phenotype, hitherto undiscovered, that appears to result from
the absence of Fbn2 protein.
Results
The Identification of the Mariusz Mutant
We carried out a mutagenesis screen to identify mouse mutants
that might possess muscular defects on the basis of exhibiting
reduced grip strength. ENU-mutagenized BALB/c males were
crossed with wild type C3H/HeH females. A female and male G1
offspring of two separate ENU-treated males were intercrossed to
maximize the number of mutations being carried in the G2
offspring. To generate homozygosity for mutations, G2 mice were
backcrossed to one of the G1 parents to generate G3 offspring that
were then screened. G3 offspring were examined for grip strength
in both forelimbs alone, and forelimbs and hindlimbs together.
One G3 pedigree (Figure 1A) contained mice with very low grip
strength (Figure 1B). This phenotype was inherited in an
autosomal recessive fashion with complete penetrance in both
sexes (Figure 1A). We named this mutant line Mariusz (after the
world’s strongest man at the time, Mariusz Pudzianowski).
In grip strength tests, the Mariusz mice were unable to grip
effectively. The paws of Mariusz mice were not closed but instead
remained in an open position with the digits extended (Figure 1C).
Although this might account for their poor performance in this
test, the overall defect in muscular strength is more profound and
involved more than an inability to grip. This was exemplified by
suspending the mice by the tail. Whereas wild type mice are able
to extend their hindlimbs for a long period of time as they struggle,
Mariusz mice could extend their hindlimbs only briefly before they
closed against their body, a so-called ‘clasping’ phenotype
(Figure 1D). This phenotype does not require any ability to grip.
They also performed poorly in the wire manoeuvre test [10]
(Figure 1E), another test for muscular strength. Indeed, the loss of
strength is so acute that mice could be accurately and simply
phenotyped for low muscular strength without any specialized
equipment, merely by holding the mice by the tail and assessing
their ability to struggle or grip a cage lid.
Concomitant with the low grip strength we noted that the mice
exhibited hindlimb paw syndactyly of two or more adjacent toes.
Both phenotypes - fused digits and weak muscular strength - are fully
penetrant in mutants but there is some variability between Mariusz
mice for the type of syndactyly. It was most commonly observed as
four toes (Figure 2A, Mz/Mz#1), though less commonly as four toes
with two of the toes fused (Figure 2A, Mz/Mz #2), four toes with
one of the toes skewed (Figure 2A, Mz/Mz#3), or occasionally, even
a mixture of two digit phenotypes in the hindlimbs of a single mouse
(Figure 2A, Mz/Mz #4). The phenotype was the result of a
combination of hard and soft tissue fusion. Alcian Blue/Alizarin Red
staining and X-rays of hindlimbs showed that digit fusion sometimes
resulted from the soft tissue fusing but leaving the phalanges unfused
(Figure 2B, Mz/Mz #1) or was the result of fusion of two, or even
three, distinct distal phalanx bones and the intervening soft tissue
(Figure 2B, Mz/Mz #2; Figure 2C).
The defect in the digits was not responsible for the low grip
strength. This is because, firstly, weak grip strength is observed in the
forelimbs alone (Figure 1B) although there are no observable digit
abnormalities in the forelimb paws. Also, as detailed above, the mice
exhibit a startling generalized muscle weakness that did not require
the ability to grip. There was 100% concordance for low grip strength
and hindlimb digit fusion in abnormal mice from this line and
heterozygotes showed no abnormal phenotype (data not shown). This
suggested that the two defects might be the result of a single mutation.
Some other phenotypic abnormalities were noted in Mariusz
mice. They performed poorly in the MoRAG test for measuring
grasping and retrieval of food pellets [11] (Figure 2D). The low
score in grasping mimics the results seen in the grip strength test.
The poor score in retrieval (where successful retrieval is scored if
the mouse brings the food toward the mouth) might indicate a
distinct abnormality in motor function. Mariusz mice also
exhibited slower growth rates than their littermate controls and
were, as a result, smaller (Figure 2E).
Positional Cloning of the Mariusz Mutation
The Mariusz mutation was generated on a BALB/cAnNCrl
genetic background, and then crossed to C3H/HeH. A total of 13
G3 C3H/HeH x BALB/cAnNCrl mice with the Mariusz
phenotype were examined with a panel of 53 markers spanning
the entire genome at regular intervals that are polymorphic
between these two strains. The strongest linkage signal (LOD
score = 3.3) was observed on chromosome 18 at a marker located
around 62 Mb. Fine mapping was achieved by backcrossing
Mariusz mice to C3H/HeH, C3H/HeN and, finally, to C57BL/
6J mice and examining mice with the Mariusz phenotype (low grip
strength and fused toes) with a panel of polymorphic markers
spanning the region. Genotyping of 310 mice derived from
intercrossing Mariusz heterozygotes identified 7 informative
recombinants that narrowed the mutation-containing region to a
maximum of 2.5 Mb (Figure 3A). At this stage we were unable to
find any further polymorphic markers in this region that
differentiated between BALB/cAnNCrl and either C3H or
C57BL/6J. According to the Ensembl database, eighteen predicted
or known genes were located within this region at the time of
sequencing. We decided to prioritize candidates for sequencing
based on gene structure and known mutant phenotypes; ENU
mutants are biased towards mutations in genes with longer coding
sequences and more exons [12]. There was one obvious candidate
gene in the region–Fbn2, with a coding sequence length of 10.5 kb
and containing 67 exons. Moreover, 4 mutants of Fbn2 had
previously been characterized, and in all these mutants digit fusion
was the defining phenotype reported [7–9].
Sequencing of Fbn2 identified a single mutation in Mariusz
mice; a T/A to A/T transversion in exon 14 of Fbn2 (Figure 3B).
The mutation results in the replacement of a codon for leucine
(TTG) by a stop codon (TAG) (Figure 3B). This truncates the
Strength in Fbn2-Null Mice
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Figure 1. The muscle weakness phenotype of the Mariusz mutant. (A) The original pedigree in which the Mariusz mutant was identified. (B)
Grip-strength comparison using 3-month-old Mariusz homozygotes (n = 30) and wild type (n = 26) littermate controls. The average force generated
by wild type mice has been set as 100%. Mean and SD are shown. The differences are highly significant; P-values (Student’s t test): *** P,0.0001. (C)
Close-up photos showing the different grasp of Mariusz homozygotes (Mz/Mz) and wild type littermate controls. (D) Example of clasping phenotype
observed in a Mariusz homozygote and littermate control. (E) A wire manoeuvre test of Mariusz mice and littermate controls. Scores are as follows:
0 =mouse swings hindlegs on to bar and makes way to edge rapidly; 1 =mouse swings hindlegs on to bar after a delay and makes way to edge
rapidly; 2 =mouse is suspended by using underarms to straddle bar and does not lift hind limbs, eventually falls; 3 =mouse falls after short delay;
4 =mouse falls immediately.
doi:10.1371/journal.pone.0009137.g001
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Figure 2. The digit fusion phenotype of the Mariusz mutant. (A) Examples of different fusion phenotypes observed - four toes (#1), four toes
with two toes fused (#2), four toes with skewed digit (#3), mixture of two digit phenotypes in a single mouse (#4). (B) Hard and soft tissue fusion
seen in Mariusz mice. Alcian Blue/Alizarin Red-stained left hindlimbs of P7 mice showing a littermate heterozygous control (left), soft tissue syndactyly
of toes 3 and 4 (centre), and syndactyly of toes 2,3 and 4 with fusion of the distal phalanges (right). (C) X-ray analysis of a hindlimb of a Mariusz
mutant demonstrating fusion of the soft tissue as well as the distal phalanx bones. (D) Morag test on Mariusz mice and wild type littermates. The
proportion of trials in which the mice were able to grasp the food pellets and retrieve the pellets to their mouths are shown. (E) Mariusz mice have a
reduced body weight. Growth curves of Mariusz male mice and littermate controls. Picture shows a typical example of the size difference between an
adult Mariusz female mouse and a littermate control at 3 months of age.
doi:10.1371/journal.pone.0009137.g002
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predicted Fbn2 protein from 2907 to 620 amino acids (Figure 3C).
There was complete concordance between animals exhibiting the
Mariusz phenotype and possessing the Fbn2 mutation. We
retrospectively regenotyped 145 DNA samples from mice with
the Mariusz phenotype and all contained the mutation.
Examination of Muscle Strength in the Fbn2fp Mutant
One aspect of our identification of this mutation was confusing.
The Mariusz mice clearly had a major defect in muscular strength,
yet this had not been reported in any of the other Fbn2 mutant mice.
There were two possible explanations for this discrepancy. Either
other Fbn2 mutants did possess this defect and the phenotype had
been missed or the muscle phenotype was not related to the Fbn2
mutation we identified but was due to a second mutation in a
neighbouring gene or intergenic region. The second possibility was
highly unlikely as, based on the known ENU-induced mutation rate
for this strain and ENU dose (1 mutation per 1.8 Mb) [13], the
probability of there being any further mutations anywhere in this
region was extremely low (P= 0.0001) [14].
Nevertheless, to formally exclude the latter possibility we
obtained another Fbn2 mutant (Fbn2fp). This Fbn2 mutation is a
single nucleotide deletion in exon 39 and results in an absence of
Fbn2 protein [8]. It had been previously documented to have
syndactyly [8] but there was no report of loss of muscular strength.
We observed that Fbn2fp/Fbn2fp homozygotes had a profound
muscle weakness and were similar to Mariusz mice in both the
clasping (Figure 4A) and the grip strength (Figure 4B) tests.
Moreover, intercrossing of Fbn2fp/Fbn2fp x Fbn2Mz/Fbn2Mz resulted
in complementation. All Fbn2fp/Fbn2Mz offspring had profound
muscle weakness and syndactyly (Figures 4A–C) similar to both
parent phenotypes indicating that the two mutations were
recessive alleles of the same gene. This is unequivocal evidence
that null mutations in Fbn2 result in a loss of muscular strength.
Physiological Assessment of Muscle in Fbn2-Null Mice
The loss of muscular strength could be due to manifestations of
the mutation in the tendons, skeletal muscle, peripheral nervous
system or central nervous system, all of which express Fbn2
[15,16]. Tendons of Fbn2-null mice have been previously analyzed
and no structural alterations were reported, though the level of
collagen cross-linking was reduced [17]. Examination of histolog-
ical sections of 5-week-old Mariusz mice and littermate controls
showed a general reduction in cross-sectional area of the muscles
of Mariusz mice (Figure 5A), which might account for at least part
of the reduction in muscular strength.
Detailed measurements of soleus muscle function were under-
taken in 4-month-old Mariusz mice and wild type controls. The
peak isometric tetanic force (P0) produced by the soleus muscle was
significantly higher in the controls compared to the Mariusz mice
(P,0.05) (Figure 5B,C). However, the peak isometric stress was
not significantly different between the control and Mariusz mice
(Figure 5D). This would suggest that the myofibrillar structure of
the muscle is unaffected by the absence of Fbn2 protein. The
difference in force between muscle from Mariusz mice and
controls in these tests could have been accounted for by the
difference in the mass of the soleus muscle (6.7260.17 mg (mean
6 SEM) in Mariusz mice compared with 3.9360.47 mg in
controls; P,0.01), and hence physiological cross-sectional area. In
part this is due to the Mariusz mice being significantly lighter than
the controls (Mariusz: 23.760.70 g (mean 6 SEM) compared to
control: 27.760.41 g (P,0.05)). However, Mariusz mice also have
relatively smaller soleus muscles than the controls (Figure 5E;
P,0.01). The maximal contraction velocity (Vmax) was not
significantly different from that of the controls (P.0.05)
(Figure 5F) and the twitch time (time to peak twitch) was not
significantly different between the two groups (P.0.05).
Mariusz Mice Exhibit Centronuclear Muscle Fibres
We examined the skeletal muscle of Mariusz mutants. Morpho-
metric analysis of fibre size showed no significant difference
between Mariusz and control mice (Figure 6A). However, an
abnormally high number of fibres with centrally placed nuclei were
evident in all muscles examined from all mice (Figure 6B, C). This
occurred consistently in all muscle samples from all mice we
examined. Such a finding is indicative of regenerating myofibres
and is considered myopathic. It is a feature of some muscle diseases
and suggests that some fibres have degenerated at some point.
There was no evidence of inflammation.
Figure 3. Genetic linkage analysis and positional cloning of the Mzmutation. (A) Genotypes of seven informative recombinants exhibiting
the Mariusz phenotype. The mutation was localized to a 2.5 Mb interval (indicated by the bracketed region). (B) Sequence of part of exon 14 of the
Fbn2 gene reveals a T-A substitution in the Mariusz allele. The reading frame of part of exon 14 is shown with the amino acid substitution that results.
(C) Schematic of the Fbn2 wild type protein and the truncation that results from the Mariusz mutation.
doi:10.1371/journal.pone.0009137.g003
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Discussion
Using ENU mutagenesis, we have identified a Fbn2 recessive
mutation that results in muscle weakness, in addition to the classic
syndactyly phenotype reported in similar Fbn2 mutants [7–9].
FBN2 mutations are responsible for many cases of CCA [2] while
mutation of the related gene FBN1 can result in Marfan’s
syndrome [1]. Marfan’s syndrome and CCA are somewhat
Figure 4. Complementation of the Fbn2Mz and Fbn2fp mutations. (A) Typical examples of the clasping phenotype of Fbn2Mz/Fbn2Mz (Mz/Mz)
and Fbn2fp/Fbn2fp (fp/fp) parents and an Fbn2Mz/Fbn2fp (Mz/fp) offspring. (B) Grip strength of mice of the three different genotypes (n = 5 males each
group). (C) Typical digit phenotypes of the Mz/Mz and fp/fp parents and a Mz/fp offspring.
doi:10.1371/journal.pone.0009137.g004
Figure 5. Muscle force measurements in Mariusz mice. (A) Morphometric measurement of cross-sectional area of Mariusz muscles in histological
sections normalized to the area of the muscle in wild type controls (n=3 mice each genotype at 5 weeks of age; n=50 fibres counted per sample). Muscle
abbreviations are: FDS, Flexor Digitorum Sublimis; FCR, Flexor Carpi Radialis; ECU, Extensor Carpi Ulnaris; ECR, Extensor Carpi Radialis. ‘Area forelimb’ refers to
the entire area of the forelimb to emphasize the size difference between Mariusz mice and littermates controls. (B) Example trace of a tetanic contraction in
a Mariusz soleus muscle and a wild type control. (C) Mean peak tetanic force for control (n=5) and Mariusz (n=6) mice with SEM shown by error bars. (D)
Mean isometric stress of the soleus muscle for wild type (n=5) and Mariusz (n=6) mice with SEM shown by error bars. (E) The mean ratio of the mass of the
soleus muscle to the mass of the mouse for control (n=5) and Mariusz (n=6) mice with SEM shown by error bars. (F) The mean maximum contraction
velocity of the soleus muscle in wild type control (n=4) and Mariusz (n=5) mice with SEM shown by error bars. P-values: * P,0.05; ** P,0.01.
doi:10.1371/journal.pone.0009137.g005
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indistinct from a clinical perspective and muscular abnormalities
have been reported in both diseases. In Marfan’s syndrome,
myopathy, as reflected in one or more of poor muscle
development, lack of response to exercise and hypotonia, is not
uncommon [18]. It has been suggested it may be present in the
majority of cases [19]. Muscular abnormalities have been reported
in CCA patients. Muscle hypoplasia, particularly of the calf
muscles, is a clinical feature of CCA [5] while atrophy has been
reported in CCA [20], or syndromes with some features of CCA
[21].
Gene targeting in embryonic stem cells has been used to
generate null alleles of Fbn1 and Fbn2 and both have proven to be
partial but imperfect models of Marfan’s syndrome and CCA
respectively. Fbn1-null mice have a similar vascular phenotype to
that of Marfan’s patients [6] while Fbn2-null mice exhibit the
transient postnatal contractures as seen in CCA [7].
Five other recessive mouse mutants have been described for
Fbn2. A null allele generated by gene targeting in embryonic stem
cells (Fbn2tm1Rmz) [7], a chemically mutagenized ES cell mutant
allele Fbn2fp-3J [9], two spontaneous mutant alleles Fbn2fp and
Fbn2fp-2J [8], and the sy mutant, which has a complete Fbn2
deletion [8,22]. Bilateral syndactyly is the main reported
phenotype in all. It is likely that these five alleles, along with the
Fbn2Mz allele, result in reduced, or complete loss of, Fbn2 function.
Both the Fbn2fp and Fbn2fp-2J mutants have deletions causing
frameshifts that result in truncation of the Fbn2 protein [8] while
the Fbn2fp-3J allele is due to a LINE insertion that also truncates
the protein [9]. In none of these cases has there be any report of
weakness in the limbs, despite the fact that our testing showed that
the Fbn2fp homozygotes previously described as exhibiting only
syndactyly [8] also suffer from muscular weakness identical to
Mariusz mice. Although we cannot confirm that the Fbn2tm1Rmz,
Fbn2fp-2J and Fbn2fp-3J alleles also result in a homozygous
phenotype of reduced strength, we feel it is highly likely given
the likely effects of these mutant alleles on the Fbn2 protein and
the similar digit fusion phenotype. As Fbn1 along with Fbn2,
contributes to myofibrils, it would be worthwhile generating mice
with a conditional null Fbn1 allele so that their muscular
phenotype could be examined.
Physiological tests on the muscle indicate that the myofibre
structure is not altered in Fbn2-null mice (as their was no
difference in peak isometric stress). The muscle itself generated less
force, probably due its relatively smaller size in Fbn2-null mice.
However, the loss of muscular strength in Fbn2-null mice is more
extreme than the reduction in the maximum force produced by
the muscle itself, suggesting an extra-muscular involvement. Our
finding that the muscle itself shows signs of degeneration/
regeneration suggests that some of the myofibres of Fbn2-null
mice are in a regenerative phase. However, there was no gross
inflammation and the level of regeneration can probably not
account for the drastic reduction in the strength of these mice. A
reduced level of collagen cross-linking has been identified in the
tendons of Fbn2-null mice [17]. As this provides structural integrity
to the tendons, the mechanical properties of the tendon, such as
Figure 6. Skeletal muscle histology in Mariusz mice. (A) Morphometric analysis of muscle fibre cross-sectional area in the soleus and
quadriceps muscles in Mariusz (n = 3) and wild type controls (n = 3). Two-way ANOVA was not significant. (B) Typical H&E sections of Mariusz
quadriceps muscle from mice at 4 and 9 weeks of age. Scale bar = 100 um. (C) Quantification of central nucleation. The number of muscle fibres with
central nuclei is represented as percentage of the total number of muscle fibres analyzed in .100 fibres. Arrows indicate centrally displaced nuclei.
Mice were aged 4 weeks and 9 weeks (n = 3 Mz/Mz; n = 3+/+). P-values (Student’s t test): * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0009137.g006
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the maximal tensile strength, might be altered as a result.
However, a reduced maximum tensile strength would make them
more susceptible to rupture, and there is no evidence of this.
We propose that there is a significant alteration in a structure or
structures external to the muscle that account for some of the loss
of strength. One possibility is that it lies within the nervous system.
In preliminary investigations, dorsal horn motor neuron counts
appeared normal (data not shown). Given that many structures
could potentially be affected, further analysis for any neuropa-
thology would be worthwhile.
Why has this muscle weakness phenotype been missed in the
original description of the Fbn2fp/Fbn2fp homozygotes? In a blind
test of several experienced animal technicians at three separate
institutes we provided with the Mariusz mice, although all were
able to identify the syndactyly phenotype quickly, none identified
the grip strength/clasping phenotype by mere handling alone.
Once they were made aware of the phenotype they were easily
able to identify mutant Fbn2-null mice with reduced strength based
on either testing the ability of the mouse to struggle when held by
the tail or testing the ability of the mouse to grip the wire grating
on a standard cage lid. Thus the phenotype, although easy to
discern without specialized equipment, required a rigorous
phenotyping assay to enable the initial identification.
Our report herein emphasizes an additional value of ENU
mutagenesis screens. Even if the mutation is of a known gene for
which a similarly acting mutation has already been identified, it
can still uncover hitherto unidentified phenotypes associated with
mutant alleles. It further emphasizes the value of extensive
phenotyping tests on mouse mutants to uncover new mutant
phenotypes [23]. Such an aim has been a driving force behind the
large-scale standardized phenotyping programmmes such as the
European Mouse Disease Clinic [24], the German Mouse Clinic
[25] and the Wellcome Trust Sanger Centre Mouse Genetics
Programme. The discovery of a new phenotype in Fbn2 mutants
emphasizes how such screens will aid in determining gene function
in the post genomic era.
Conclusion
We have identified a new phenotype - loss of strength - resulting
from absence of Fbn2. The loss of strength is at least partly the
result of relatively smaller muscles in Fbn2-null mice, but extra-
muscular effects account for a significant proportion of the
strength loss. Given that muscular weakness and muscular atrophy
are common findings in patients suffering from Marfan’s
syndrome and CCA, Fbn2-null mice may be a good model for
investigating this aspect of the disease further.
Materials and Methods
Mice
Mice were maintained in high health status facilities according
to the UK Home Office guidelines with access to food and water
ad libidum. Fbn2fp mice were obtained from the Jackson
Laboratories. All animal studies were approved both the ethical
committees of the Medical Research Council, Harwell, University
of Sheffield and University of Leeds as well as by the UK Home
Office.
ENU Mutagenesis
Adult BALB/cAnNCrl mice aged 10 weeks were mutagenized
by intraperitoneal injection of two weekly doses of 100 mg/kg
ENU and after recovery of fertility were mated with C3H/HeH.
F1 offspring were intercrossed and the G2 offspring were
backcrossed to G1 parents to generate the G3 generation for
screening.
Phenotyping Tests
Mice were assessed for their performance in the grip strength
test using a mouse grip strength meter (Bioseb, Vitrolles Cedex,
France). Mice were held by the tail and removed from their cage.
They were gently lowered onto the grid and allowed to place
either all four paws, or their forelimb paws only, on the mesh. The
mice were then gently pulled back steadily and slowly across the
grid while recording the maximum grip strength in Newtons. For
each animal 4 measurements were taken to obtain an average
value for grip strength for each mouse. For the wire manoeuvre
test, the method and scoring system of Rafael et al. [10] was used.
The MORAG test was performed and scored as previously
described [11].
Genetic Mapping
Genome-wide low-resolution mapping was performed using
DNA samples from 13 G3 hybrids. Genomic DNA samples
isolated from tail biopsies of these animals were screened by PCR
amplification and gel electrophoresis with 53 microsatellite
markers spaced at regular intervals across the genome. For finer
mapping, the Mariusz mutation was sequentially backcrossed and
intercrossed on both C3H/HeN and C57BL/6J backgrounds.
Microsatellite markers polymorphic between either BALB/c and
C3H or BALB/c and C57BL/6J were used to identify Mariusz
mice that were recombinant in the critical region. Single
nucleotide polymorphisms (SNPs) were genotyped by sequencing
of PCR products amplified with primers flanking the SNP site.
Sequencing of candidate genes involved designing primer pairs to
amplify individual exons as well as flanking splice donor/acceptor
sequences. For DNA sequencing, all exons and splice sites of
selected genes were sequenced using homozygous Mariusz DNA
and compared to wild type DNA from all strains.
Genotyping of Cohorts for Experimental Analysis
For experimental analysis of mutant and wild type cohorts, mice
were deemed to be carrying the mutation if they either contained
BALB/c-derived markers for the region containing the Mariusz
mutation on chromosome 16 or later, after the mutation was
identified, by direct sequencing of PCR products to identify if they
carried the T-A mutation in Fbn2.
H&E of Skeletal Muscle
The quadriceps and triceps muscle from Mariusz and C57BL/
6J age-matched mice were dissected and formalin fixed before
being embedded in paraffin wax. Transverse sections were taken
and stained with haematoxylin and eosin.
Muscle Physiology
Mice were sacrificed by cervical dislocation. The soleus muscle
was immediately dissected out from the hindlimb in oxygenated
Krebs-Henseleit Ringers solution at 3uC [composition in mmol
l21: NaCl, 118.5; NaHCO3, 25.0; KCl, 4.8; MgSO4, 1.2;
KH2PO4, 1.2; CaCl2, 1.4; glucose, 11.0; saturated with 95%
O2, 5%CO2 [26]. The proximal end of the muscle was attached to
the base of a PerspexTM muscle chamber using a stainless steel
spring clip to clamp the proximal tendon. The muscle was
attached to the arm of a muscle lever (model 300B-LR, Aurora
Scientific, Aurora, ON, Canada) via a lightweight silver chain
attached to the distal tendon of the soleus muscle using 5-0 silk
suture. The soleus muscle was held vertically within the muscle
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chamber that was circulated with oxygenated Krebs-Henseleit
Ringer’s solution. The temperature of the Ringer’s solution was
gradually increased from 3uC to 37uC over a period of
approximately 15 minutes. The muscle was left for at least 30
minutes following the dissection before the contractile properties
were measured.
A series of isometric twitches were used to set the length of the
muscle to that at which maximum twitch force was produced (L0).
Supramaximal stimuli were delivered via parallel platinum
electrodes running alongside the muscle (pulse width 0.25 ms).
The motor arm of the muscle lever was mounted on an adjustable
stand that enabled the length of the muscle to be varied. An
isometric tetanic contraction was produced using a train of stimuli
delivered at the fusion frequency of the muscle (typically 150 Hz).
Muscle force was recorded at 5 kHz via an A/D board
(DAS1802AO, Keithley Instruments, Theale, UK) and the
maximal isometric tetanic force produced by the muscle (P0)
calculated. Force-velocity characteristics were determined during
after-loaded isotonic tetanic contractions. Muscle length was set to
1.05 L0 so that the muscle shortened through the plateau of the
length-force relationship. The muscle was maximally stimulated;
force was allowed to rise to a predefined level (ranging from
approximately 5 to 80% of P0) and was then held constant by
muscle shortening. Further isometric tetanic contractions were
performed periodically during and at the end of the series of
isotonic contractions as references of maximum isometric force in
order to monitor and correct for any decline in muscle
performance. Any decline was assumed to be linear between
controls. Muscle force (P) and length were recorded at 5 kHz via
an A/D board (DAS1802AO, Keithley Instruments, Theale, UK).
Muscle length (L) was converted to strain [(L2L0)/L0]. Strain was
differentiated with respect to time in order to determine velocity.
This was plotted against corrected relative force (P/P0). A
hyperbolic-linear relationship was fit to these data and the
maximum velocity of shortening (Vmax) estimated by extrapolation
to zero force [27].
Following the measurements of the contractile properties of the
muscle, the muscle was blotted and weighed. The physiological
cross-sectional area of the muscle was calculated by dividing the
muscle mass by mean fibre length (0.85 L0) [28] and dividing by
muscle density (1060 kg m23) [29]. Maximum muscle stress was
calculated as P0 divided by physiological cross-sectional area.
Software and Databases
DNA sequence alignments for examining sequence data were
performed using DNASTAR (DNASTAR Inc. Madison, WI).
Prism software (GraphPad Software, Inc., La Jolla, CA) was used
for statistical analysis. Morphometric analysis of muscle fibre cross-
sectional area was estimated using Image J [30]. For meaurement
of fibre cross-sectional area, contrast of micrographs was enhanced
by 0.5%. The freehand tool was then used to mark individual
fibres.
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